No Data
Duorui Medicine (301075.SZ): Currently, all workshops built by Xinchengda have been put into production, and the production operation situation is normal.
On January 10, Gelonghui reported that Duori Pharmaceutical (301075.SZ) stated on the investor interaction platform that all the workshops of Xinchengda have been put into production, and the production and Operation situation is normal. For specific details, please pay attention to the company's announcements and regular reports.
Duori Pharmaceutical (301075.SZ): Own products have not yet been developed for influenza or antiviral treatment.
Gelonghui, January 10 - Duory Pharmaceutical (301075.SZ) stated on the investor interaction platform that the company's ibuprofen suspension is produced based on a sales-driven production model, and the company's own products have not yet been developed for the treatment of influenza or viral infections.
Duori Pharmaceutical (301075.SZ): Sodium Acetate Ringer's Injection (specification packaging 500ml/bag) is expected to be selected for centralized procurement.
On December 16, Gelonghui reported that Duroy Pharmaceutical (301075.SZ) announced that its wholly-owned subsidiary Hubei Duroy Pharmaceutical Co., Ltd. recently participated in the bidding of the tenth batch of national organized centralized procurement of pharmaceuticals organized by the National Organization of Pharmaceutical Joint Procurement Office. According to the public notice of the proposed selected results, the company’s product sodium acetate Ringer's injection (package specification 500ml/bag) is proposed to be selected for this centralized procurement, while sodium bicarbonate Ringer's injection was not selected for this centralized procurement.
Doray Pharmaceuticals (301075.SZ): The target of the acquisition has passed the pharmaceutical GMP compliance inspection and the active pharmaceutical ingredient has been approved for listing.
Gelonghui Nov 6th │ Duorui Pharmaceuticals (301075.SZ) announced that recently, the company's controlling subsidiary, Changdu Rui Le Kang Enterprise Management Co., Ltd., intends to acquire the subject Sichuan FrontBio Pharmaceutical Co., Ltd., approved by the National Medical Products Administration to issue the "Chemical Raw Materials Pharmaceuticals Market Application Approval Notice" (No.: 2024YS01126), approved for domestic production of Ecokin chemical raw materials pharmaceuticals; at the same time, Sichuan FrontBio recently received the "Pharmaceutical GMP Compliance Inspection Notice" (Chuanxu 2024179) issued by the Sichuan Provincial Medical Products Administration, Ecokin active pharmaceutical ingredient production line has passed.
Duorui Pharmaceuticals (301075.SZ): Intends to transfer 5.66% equity of Hubei Tianji for 68.8 million yuan.
Adlinsight November 4th | Dorley Pharmaceuticals (301075.SZ) announced that on November 4, 2024, the board of directors held the seventeenth meeting of the second session and the board of supervisors held the sixteenth meeting of the second session, deliberating and approving the "Proposal on transferring all equity of the equity-participating company and signing the Equity Transfer Agreement", agreeing to transfer the 5.66% equity held in Hubei Tianji Pharmaceutical Co., Ltd. (hereinafter referred to as "Hubei Tianji") for a total of RMB 68.8 million to Hubei Qingsong Yueyue Medicine Co., Ltd. (hereinafter referred to as "Qingsong Yueyue"). After the completion of the above transaction, the company will no longer hold equity in Hubei Tianji.
Duorui Pharmaceutical (301075.SZ): Linsidomine sodium acetate injection passed the consistency evaluation.
DuoRui Pharmaceutical (301075.SZ) announced that its wholly-owned subsidiary Hubei DuoRui Pharmaceutical Co., Ltd. (referred to as 'hubei...
